FeesSafety
Pluang+

Co-Diagnostics reports Q3 revenue rise, operating expense drop, and two key regulatory submissions under review.

Company Fundamentals
10 Nov 2026, 15:00 WIB
PRNewsWire
View Source
Bullish
Co-Diagnostics reports Q3 revenue rise, operating expense drop, and two key regulatory submissions under review.

Co-Diagnostics announced its Q3 2026 financial results, showing revenue growth to $0.3 million and a 12% reduction in operating expenses year-over-year. The company has two regulatory submissions under review: a tuberculosis test in India and a Flu A/B & RSV test in the U.S. It also expanded its platform capabilities with new collaborations and international deployments. Despite a net loss of $6.3 million, Co-Diagnostics is advancing product development and regulatory approvals to drive future growth.

Co-Diagnostics' Q3 2026 financial results provide context for readers interested in health-sector developments. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 10, 2026 18:42 WIB: Among 150 priced US health-sector stocks tradable on Pluang, 85 rose and 56 fell today. Notable movers include FLNA at USD 0.53 with a 7.80% increase and a typical hold time of 39 days, CGC at USD 0.65 up 4.37% with a 40-day hold time, and ABCL at USD 12.96 rising 3.68% with a 42-day hold time. Pluang order activity shows predominantly sell interest for these stocks.

More News

Duke Robotics expands IC Drone platform to Greece via strategic deal with CRONOS for energy sector projects

Duke Robotics expands IC Drone platform to Greece via strategic deal with CRONOS for energy sector projects

Duke Robotics has entered a strategic collaboration with Greek security firm CRONOS to commercialize its Insulator Cleaning Drone (IC Drone) technology in Greece. This partnership leverages CRONOS's strong presence in Greece's critical infrastructure...

Market News
Bullish
1 hour ago
Alm. Brand A/S buys back 1.37 million shares, holding 3.89% of total shares as part of ongoing repurchase program.

Alm. Brand A/S buys back 1.37 million shares, holding 3.89% of total shares as part of ongoing repurchase program.

Alm. Brand A/S repurchased 1,369,397 shares between November 3 and 9, 2026, at an average price of DKK 17.46 per share. This is part of their announced buy-back program totaling up to DKK 593 million, aiming to reduce the number of outstanding shares...

Company Fundamentals
Neutral
1 hour ago
H&R Block offers Emerald Advance Loan up to $1,750 with no monthly payments, due March 2027.

H&R Block offers Emerald Advance Loan up to $1,750 with no monthly payments, due March 2027.

H&R Block has launched the Emerald Advance Loan, a fixed-rate short-term loan up to $1,750 with a 35.90% APR, designed to help families cover year-end expenses without monthly payments. Borrowers repay the loan in full by March 31, 2027, with no impa...

Market News
Bullish
1 hour ago
Novartis tops 2026 Access to Medicine Index, leading in all technical areas for expanding global medicine access.

Novartis tops 2026 Access to Medicine Index, leading in all technical areas for expanding global medicine access.

Novartis has secured first place in the 2026 Access to Medicine Index, maintaining its lead since 2024 by excelling across all assessed technical areas, including governance, R&D, and product delivery. The company scored 3.86 out of 5 overall, with a...

Market News
Bullish
1 hour ago
Viasat wins $450M U.S. Space Force contract to develop Space Data Network Backbone operations center.

Viasat wins $450M U.S. Space Force contract to develop Space Data Network Backbone operations center.

Viasat has been awarded a $450 million IDIQ contract by the U.S. Space Force to support the design, development, and sustainment of the Space Data Network Backbone (SDN-B) mission operations center. This network aims to provide resilient, high-capaci...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App